The anti-inflammatory and immune-modulatory effects of OEA limit DSS-induced colitis in mice

Lama, Adriano; Provensi, Gustavo; Amoriello, Roberta; Pirozzi, Claudio; Rani, Barbara; Mollica, Maria Pina; Raso, Giuseppina Mattace; Ballerini, Clara; Meli, Rosaria; Passani, Maria Beatrice

doi:10.1016/j.biopha.2020.110368

Cited by 34 publications

(34 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The animal model for IBS exhibits many similar characteristics to human studies, which include diarrhea-associated inflammation, weight loss, immune cell infiltration, and activation with altered macrophage functions [ 11 ]. The most suitable and commonly used animal model to study experimental colitis is induced by administering dextran sodium sulfate (DSS), a chemical colitogen with anticoagulant properties, to understand IBD pathogenesis [ 12 ].…”

mentioning

confidence: 99%

Ibrutinib attenuated DSS-induced ulcerative colitis, oxidative stress, and inflammatory cascade by modulating PI3K/Akt and JNK/NFκB pathways

et al. 2022

View full text Add to dashboard Cite

mentioning

confidence: 99%

Ibrutinib attenuated DSS-induced ulcerative colitis, oxidative stress, and inflammatory cascade by modulating PI3K/Akt and JNK/NFκB pathways

et al. 2022

View full text Add to dashboard Cite

“…The increase in these proteins was alleviated by OEA addition to the diet [ 100 ]. The OEA anti-inflammatory effects were also evident in dextran sulfate sodium (DSS)-induced mice colitis, and the effect was mediated by the inhibition of NLRP3, NF-κB, or MyD88-dependent pathways [ 101 ].…”

Section: Peroxisome Proliferator-activated Receptor Alpha (Pparα) and Its Role In Inflammationmentioning

confidence: 99%

The Role of PPAR Alpha in the Modulation of Innate Immunity

Grabacka

Pierzchalska

Płonka

et al. 2021

IJMS

View full text Add to dashboard Cite

Peroxisome proliferator-activated receptor α is a potent regulator of systemic and cellular metabolism and energy homeostasis, but it also suppresses various inflammatory reactions. In this review, we focus on its role in the regulation of innate immunity; in particular, we discuss the PPARα interplay with inflammatory transcription factor signaling, pattern-recognition receptor signaling, and the endocannabinoid system. We also present examples of the PPARα-specific immunomodulatory functions during parasitic, bacterial, and viral infections, as well as approach several issues associated with innate immunity processes, such as the production of reactive nitrogen and oxygen species, phagocytosis, and the effector functions of macrophages, innate lymphoid cells, and mast cells. The described phenomena encourage the application of endogenous and pharmacological PPARα agonists to alleviate the disorders of immunological background and the development of new solutions that engage PPARα activation or suppression.

show abstract

“…Treatment with PEA also resulted in amelioration of intestinal inflammation in animal and human models of inflammatory bowel disease (Borrelli et al, 2015). PEA treatment, indeed, dose‐dependently decreased the expression and release of pro‐inflammatory cytokines as well as neutrophil and macrophage infiltration in both dextran sodium sulfate‐induced ulcerative colitis (UC) in mice as well as in cultured human biopsies deriving from UC patients (Lama et al, 2020). Importantly, PEA is also able to downregulate, via a PPARα‐dependent mechanism, the expression of Toll‐like receptor 4 (TLR4) in both enteric glial cells and vascular smooth cells (Sarnelli, D'Alessandro, et al, 2016).…”

Section: Pea Immunomodulatory Activitymentioning

confidence: 99%

Phytotherapics in COVID19: Why palmitoylethanolamide?

Pesce

Seguella

Cassarano

et al. 2020

Phytotherapy Research

View full text Add to dashboard Cite

At present, googling the search terms "COVID-19" and "Functional foods" yields nearly 500,000,000 hits, witnessing the growing interest of the scientific community and the general public in the role of nutrition and nutraceuticals during the COVID-19 pandemic. Many compounds have been proposed as phytotherapics in the prevention and/or treatment of COVID-19. The extensive interest of the general public and the enormous social media coverage on this topic urges the scientific community to address the question of whether which nutraceuticals can actually be employed in preventing and treating this newly described coronavirus-related disease. Recently, the Canadian biotech pharma company "FSD Pharma" received the green light from the Food and Drug Administration to design a proof-of-concept study evaluating the effects of ultramicronized palmitoylethanolamide (PEA) in COVID-19 patients. The story of PEA as a nutraceutical to prevent and treat infectious diseases dates back to the 1970s where the molecule was branded under the name Impulsin and was used for its immunomodulatory properties in influenza virus infection. The present paper aims at analyzing the potential of PEA as a nutraceutical and the previous evidence suggesting its anti-inflammatory and immunomodulatory properties in infectious and respiratory diseases and how these could translate to COVID-19 care.

show abstract

The anti-inflammatory and immune-modulatory effects of OEA limit DSS-induced colitis in mice

Cited by 34 publications

References 42 publications

Ibrutinib attenuated DSS-induced ulcerative colitis, oxidative stress, and inflammatory cascade by modulating PI3K/Akt and JNK/NFκB pathways

Ibrutinib attenuated DSS-induced ulcerative colitis, oxidative stress, and inflammatory cascade by modulating PI3K/Akt and JNK/NFκB pathways

The Role of PPAR Alpha in the Modulation of Innate Immunity

Phytotherapics in COVID19: Why palmitoylethanolamide?

Contact Info

Product

Resources

About